Privium Fund Management
IONS icon

Privium Fund Management’s Ionis Pharmaceuticals IONS Stock Holding History

Privium Fund Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$15.6M Buy
349,003
+29,079
+9% +$1.65M 3.02% 10
2026
Q2 		$25.4M Buy
319,924
+29,900
+10% +$2.25M 4.66% 5
2026
Q1 		$21.8M Buy
290,024
+49,200
+20% +$3.88M 4.53% 7
2025
Q4 		$19.1M Sell
240,824
-8,070
-3% -$608K 3.51% 7
2025
Q3 		$16.3M Sell
248,894
-18,700
-7% -$913K 2.93% 10
2025
Q2 		$10.7M Hold
267,594
– – 2.31% 9
2025
Q1 		$8.07M Buy
267,594
+800
+0.3% +$26.2K 2.1% 8
2024
Q4 		$9.33M Buy
266,794
+16,050
+6% +$600K 2.11% 12
2024
Q3 		$10M Buy
250,744
+3,477
+1% +$162K 2.5% 11
2024
Q2 		$11.2M Buy
247,267
+20,274
+9% +$832K 2.85% 9
2024
Q1 		$9.8M Buy
226,993
+9,500
+4% +$453K 2.63% 11
2023
Q4 		$11.5M Sell
217,493
-11,000
-5% -$527K 3.2% 7
2023
Q3 		$10.4M Buy
228,493
+2,000
+0.9% +$82.5K 3.08% 8
2023
Q2 		$9.31M Buy
226,493
+43,720
+24% +$1.68M 2.68% 13
2023
Q1 		$6.53M Buy
182,773
+33,966
+23% +$1.28M 2.19% 17
2022
Q4 		$5.56M Hold
148,807
– – 2.11% 16
2022
Q3 		$6.59M Sell
148,807
-31,300
-17% -$1.32M 2.39% 11
2022
Q2 		$6.67M Hold
180,107
– – 2.21% 14
2022
Q1 		$6.67M Sell
180,107
-450,092
-71% -$14.7M 1.47% 23
2021
Q4 		$19.2M Buy
+630,199
New +$19.8M 3.82% 7

Other funds holding IONS

Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Pinnacle Associates
Pinnacle Associates New York $8.92B AUM 43.91% 1-Year Est. Return
Nippon Life Global Investors Americas
Nippon Life Global Investors Americas New York $2.51B AUM 38.65% 1-Year Est. Return
Sicart Associates
Sicart Associates New York $413M AUM 28.3% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
CenterBook Partners
CenterBook Partners Greenwich, Connecticut $2.18B AUM 12.5% 1-Year Est. Return
China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return
Motley Fool Asset Management
Motley Fool Asset Management Alexandria, Virginia $2.64B AUM 26.58% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Privium Fund Management's IONS Position: Q3 2026 in Review

Privium Fund Management increased its Ionis Pharmaceuticals (IONS) stake by 9.1% in Q3 2026, buying an estimated $1.65M and bringing the position to 349,003 shares worth $15.6M. The position accounts for 3.02% of the portfolio, ranked #10.

Privium Fund Management first reported a position in IONS in Q4 2021 and has held it in 20 quarters since. The position peaked at $25.4M in Q2 2026. 134 funds tracked by Wall St. Rank hold IONS as of Q3 2026.

  • Privium Fund Management held 349,003 shares of Ionis Pharmaceuticals worth $15.6M as of Q3 2026.
  • Privium Fund Management bought 29,079 Ionis Pharmaceuticals shares in Q3 2026, an estimated $1.65M.
  • Ionis Pharmaceuticals made up 3.02% of Privium Fund Management's portfolio in Q3 2026, its #10 holding.
  • Privium Fund Management first reported a position in Ionis Pharmaceuticals in Q4 2021 and has held it in 20 quarters since.
  • Privium Fund Management's Ionis Pharmaceuticals position peaked at $25.4M in Q2 2026.
  • 134 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2026.

Based on Privium Fund Management's 13F filing for Q3 2026, filed 3 Nov 2026.